Curis (CRIS) Non-Current Assets (2010 - 2026)
Curis' (CRIS) quarterly Non-Current Assets came in at $13.1 million in Q1 2026, down 9.92% YoY from $14.5 million in Q1 2025, and little changed on a QoQ basis from $13.1 million in Q4 2025.
Curis (CRIS) Non-Current Assets (2010 - 2026) Analysis & Trends
Curis (CRIS) has 17 years of Non-Current Assets data on file, last reported at $13.1 million in Q1 2026.
- Quarterly Non-Current Assets fell 9.92% year-over-year to $13.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54.7 million (down 10.1% YoY) and the FY2025 annual result came in at $13.1 million, down 12.29% from the prior year.
- Non-Current Assets was little changed at $13.1 million in Q1 2026, from $13.1 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $17.1 million in Q3 2022 to a low of $13.1 million in Q4 2025.
- A 5-year average of $15.4 million and a median of $15.5 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets plunged 58.1% — and 2023, when it climbed 13.25%.
- Tracing CRIS's Non-Current Assets over 5 years: stood at $16.7 million in 2022, then dropped by 2.12% to $16.4 million in 2023, then declined by 9.12% to $14.9 million in 2024, then dropped by 12.29% to $13.1 million in 2025, then advanced by 0.18% to $13.1 million in 2026.
- The last three Non-Current Assets figures came in at $13.1 million (Q1 2026), $13.1 million (Q4 2025), and $13.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Curis | 3.44 Mn | -2.18 Mn | - | 12.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.08 Mn |
| Dec 31, 2025 | 13.05 Mn |
| Sep 30, 2025 | 13.73 Mn |
| Jun 30, 2025 | 14.82 Mn |
| Mar 31, 2025 | 14.52 Mn |
| Dec 31, 2024 | 14.88 Mn |
| Sep 30, 2024 | 15.54 Mn |
| Jun 30, 2024 | 15.89 Mn |
| Mar 31, 2024 | 15.96 Mn |
| Dec 31, 2023 | 16.37 Mn |
| Sep 30, 2023 | 16.55 Mn |
| Jun 30, 2023 | 16.46 Mn |
| Mar 31, 2023 | 16.53 Mn |
| Dec 31, 2022 | 16.73 Mn |
| Sep 30, 2022 | 17.14 Mn |
| Jun 30, 2022 | 15.44 Mn |
| Mar 31, 2022 | 14.60 Mn |
| Dec 31, 2021 | 39.93 Mn |
| Sep 30, 2021 | 37.14 Mn |
| Jun 30, 2021 | 24.66 Mn |